Replimune Group, Inc. (NASDAQ:REPL) Receives $10.00 Consensus Target Price from Brokerages

Replimune Group, Inc. (NASDAQ:REPL) has earned a consensus rating of “Hold” from the ten analysts that are currently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating on the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $10.00.

Several research firms have recently commented on REPL. Piper Sandler upped their price objective on shares of Replimune Group from $13.00 to $14.00 and gave the company an “overweight” rating in a report on Thursday, February 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Replimune Group in a research report on Monday, December 29th. Finally, Wedbush upped their price target on shares of Replimune Group from $18.00 to $19.00 and gave the company an “outperform” rating in a report on Wednesday, February 4th.

Replimune Group Stock Up 14.6%

Shares of REPL stock opened at $8.07 on Monday. Replimune Group has a fifty-two week low of $2.68 and a fifty-two week high of $13.24. The firm has a market capitalization of $666.34 million, a PE ratio of -2.35 and a beta of 0.72. The company has a debt-to-equity ratio of 0.33, a quick ratio of 5.60 and a current ratio of 5.60. The stock’s 50-day simple moving average is $7.89 and its 200-day simple moving average is $7.57.

Replimune Group (NASDAQ:REPL) last released its earnings results on Tuesday, February 3rd. The company reported ($0.77) EPS for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.08. Equities analysts expect that Replimune Group will post -2.97 earnings per share for the current year.

Insider Activity

In other news, Director Kapil Dhingra sold 3,169 shares of the company’s stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $10.40, for a total value of $32,957.60. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 5.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Replimune Group

Several hedge funds have recently bought and sold shares of REPL. International Assets Investment Management LLC purchased a new position in shares of Replimune Group during the 4th quarter valued at approximately $29,000. Russell Investments Group Ltd. boosted its holdings in Replimune Group by 3,638.9% during the third quarter. Russell Investments Group Ltd. now owns 7,777 shares of the company’s stock worth $33,000 after buying an additional 7,569 shares in the last quarter. CWM LLC boosted its holdings in Replimune Group by 248.6% during the fourth quarter. CWM LLC now owns 4,047 shares of the company’s stock worth $39,000 after buying an additional 2,886 shares in the last quarter. BNP Paribas Financial Markets grew its position in Replimune Group by 99.8% during the third quarter. BNP Paribas Financial Markets now owns 13,762 shares of the company’s stock valued at $58,000 after buying an additional 6,873 shares during the period. Finally, Raymond James Financial Inc. acquired a new stake in Replimune Group during the second quarter valued at $69,000. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.